K2B Therapeutics is developing protein-drug/siRNA conjugates with the potential for tumor-agnostic treatment of cancer. Our team believes that K2B's conjugates will revolutionize cancer therapeutics and address significant unmet need.
The foundational technology was developed at KIST (Korea Institute of Science and Technology).
Company Details
- Employees
- 10
- Founded
- 2021
- Address
- 238 Main Street, Cambridge,ma 02142,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Cambridge, MA
K2b Therapeutics Questions
K2B Therapeutics's LinkedIn profile is https://www.linkedin.com/company/k2b-therapeutics
K2B Therapeutics has
10 employees.
View email and phone details for 10
employees at K2B Therapeutics.
K2B Therapeutics's industry is
Biotechnology Research
K2B Therapeutics's top competitors are
Vesigen Therapeutics, Inc.,
Fletcher Biosciences,
Paq Therapeutics,
Treefrog Therapeutics,
Inndura Therapeutics,
Nextpoint Therapeutics, Inc.,
Stipple Bio,
Harton,
March Therapeutics,
Kernal Biologics.
K2B Therapeutics's categories are Biotechnology Research
K2B Therapeutics's founding year is 2021
